Conditions Dr. Omar Calderon Treats

Ibogaine's most well-documented application. By resetting opioid receptors directly, ibogaine eliminates acute withdrawal symptoms within hours of administration and dramatically reduces post-treatment cravings. Patients who have spent years dependent on opioids often describe the experience as neurologically starting over.

Fentanyl's extraordinary potency and short half-life create unique withdrawal challenges. MindScape's protocol specifically addresses fentanyl's pharmacokinetic profile with careful pre-treatment management and individualized dosing strategy. Our outcomes with fentanyl patients are among the most documented in the field.

Suboxone's high mu-opioid receptor affinity requires a structured taper to low dose (typically 2–4mg/day) followed by a defined washout period before ibogaine can be safely administered. MindScape's medical team designs individualized taper schedules that make this transition as manageable as possible before treatment begins.

Kratom's partial opioid agonism responds well to ibogaine's receptor reset. Most kratom-dependent patients achieve resolution of withdrawal and significant craving reduction in a single treatment session, making this one of the more straightforward ibogaine applications.

Ibogaine interrupts the reward pathways underlying alcohol dependence by modulating dopamine and serotonin systems. Patients report dramatic reduction in alcohol cravings and often a fundamental shift in their relationship with alcohol. Best results occur when combined with robust integration support.

Stimulant addiction involves dopaminergic reward pathways that ibogaine directly modulates. While the mechanism differs from opioid receptor reset, patients consistently report significant reduction in stimulant cravings and improved capacity for abstinence following treatment.

Ibogaine facilitates deep neurological processing of traumatic memory — not by suppressing it, but by enabling the brain to integrate it differently. Veterans and trauma survivors consistently report significant reduction in PTSD symptoms, hypervigilance, and intrusive thoughts following treatment. MindScape has developed a specialized protocol for this population.

GDNF upregulation and neuroplasticity promotion make ibogaine particularly promising for TBI. Patients report improved cognitive clarity, reduced headache frequency, better sleep, and mood stabilization. The neuroprotective mechanism is the basis for ongoing research interest in this application.

Ibogaine's rapid antidepressant effect operates through neuroplasticity, GDNF upregulation, and serotonergic modulation — entirely different from conventional antidepressants. Many patients who have failed three or more antidepressant trials report significant mood improvement within days of ibogaine treatment.

The introspective phase of ibogaine treatment often produces profound shifts in the cognitive and emotional patterns underlying chronic anxiety. While not ibogaine's primary indication, many patients treated for other conditions report significant secondary improvement in anxiety symptoms.

MindScape Retreat is among the very few centers offering ibogaine for Parkinson's disease. The medical team leverages ibogaine's GDNF upregulation and dopaminergic neuron repair capabilities to address motor and non-motor symptoms. Published case studies document significant improvements in motor function, rigidity, and quality of life.

SSRI discontinuation syndrome can be severe and prolonged. MindScape's 10–14 day protocol helps patients safely stop antidepressants by resetting the serotonin system under continuous physician supervision. Patients must complete a careful taper before ibogaine administration due to dangerous drug interaction potential.

An emerging application area for ibogaine based on its neuroprotective mechanisms. Some MS patients have reported symptomatic improvements following treatment. Each case is evaluated individually, applying the same rigorous screening standards to determine candidacy.